191220-79-8Relevant articles and documents
Synthetic studies on selective type 4 phosphodiesterase (PDE 4) inhibitors. 1. Structure-activity relationships and pharmacological evaluation of 1,8-naphthyridin-2(1H)-one derivatives.
Takayama, Kazuhisa,Iwata, Masahiro,Hisamichi, Hiroyuki,Okamoto, Yoshinori,Aoki, Motonori,Niwa, Akira
, p. 1050 - 1059 (2007/10/03)
In order to develop novel and orally active phosphodiesterase (PDE) 4 inhibitors, random screening was performed using our chemical library to find YM-10335 possessing the 1,8-naphthyridin-2(1H)-one skeleton which is a completely different structure from rolipram. In this report, the syntheses and structure-activity relationships of the YM-10335 derivatives were described. Some compounds showed selective inhibitory activities for PDE 4 derived from human peripheral blood cells and no effect on the other PDE types (1, 2, 3, 5). The inhibition of the tumor necrosis factor-alpha (TNF-alpha) release in vitro and the carrageenan-induced pleurisy in rats were also described.
Pyrido[2,3-D]pyrimidine derivatives and pharmaceutical compositions thereof
-
, (2008/06/13)
PCT No. PCT/JP96/03389 Sec. 371 Date Apr. 30, 1998 Sec. 102(e) Date Apr. 30, 1998 PCT Filed Nov. 20, 1996 PCT Pub. No. WO97/19078 PCT Pub. Date May 29, 1997This invention relates to compounds (I) or pharmaceutically acceptable salts thereof, having a func